Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Basilea Pharmaceutica Ltd
Basilea Pharmaceutica Ltd
Activities:
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Andelyn Biosciences and Grace Science, LLC partner to manufacture AAV gene therapy
The partnership will seek to maximise programme efficiency, support the ongoing clinical trial and accelerate this critical therapy to patients
Teva UK and Closed Loop Medicine partner to advance personalised medicine development
SaMD platform aims to advance personalised medicine development, improve drug efficacy and patient outcomes with specific chronic conditions
Henkel facilities receive EXCiPACT certificate as suppliers of pharmaceutical excipients
The certification means Henkel meets EXCiPACT’s guidelines for good manufacturing practice (GMP) and good distribution practice (GDP)
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Research & Development
Spexis sells preclinical antibiotics programme to Basilea
The CHF 2m deal gives Basilea ownership of a novel programme of Gram-negative bacteria-targeting antibiotics
Finance
Spexis announces sale of preclinical antibiotics programme to Basilea
Basilea to pay up to CHF2m for a preclinical programme with novel antibiotics targeting Gram-negative bacteria, including multidrug-resistant strains
Research & Development
Forge and Basilea partner on antibiotic discovery
Forge Therapeutics’s platform will be used by Basilea Pharmaceutica to develop inhibitors against two historically difficult-to-drug, unexploited antibiotic targets
Research & Development
Basilea awarded up to US$100m contract from BARDA
To advance clinical Phase III programme for ceftobiprole antibiotic
You need to be a subscriber to read this article.
Click here
to find out more.
Regulatory
Latest EU drug approvals span range of health issues
Cancer was again at the forefront of the NMEs reaching the market in 2015, but new drugs also benefited other disease areas. Dr Sarah Houlton looks at the latest therapeutic arrivals
Research & Development
Basilea's Chief Technology Officer to retire
Dr Günter Ditzinger named as successor Dr Ingrid Heinze-Krauss
Research & Development
Consortium signs deal with Basilea to develop targeted cancer therapy
Clinical Phase I testing of panRAF kinase inhibitors is expected to start this year
Subscribe now